Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Abvc Biopharma (ABVC) over the last 4 years, with Q3 2025 value amounting to $81115.0.

  • Abvc Biopharma's Current Deferred Revenue rose 203.14% to $81115.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $81115.0, marking a year-over-year increase of 203.14%. This contributed to the annual value of $81115.0 for FY2024, which is 203.14% up from last year.
  • As of Q3 2025, Abvc Biopharma's Current Deferred Revenue stood at $81115.0, which was up 203.14% from $81115.0 recorded in Q2 2025.
  • Abvc Biopharma's 5-year Current Deferred Revenue high stood at $81115.0 for Q4 2024, and its period low was $10985.0 during Q4 2022.
  • Its 4-year average for Current Deferred Revenue is $73858.8, with a median of $79501.0 in 2023.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 62371.42% in 2023, then decreased by 0.13% in 2024.
  • Over the past 4 years, Abvc Biopharma's Current Deferred Revenue (Quarter) stood at $10985.0 in 2022, then skyrocketed by 623.71% to $79500.0 in 2023, then increased by 2.03% to $81115.0 in 2024, then changed by 0.0% to $81115.0 in 2025.
  • Its Current Deferred Revenue stands at $81115.0 for Q3 2025, versus $81115.0 for Q2 2025 and $81115.0 for Q1 2025.